



VGX Pharmaceuticals Announces Publication of Preclinical Animal Efficacy Studies for VGX-150 in *Molecular Therapy*

Blue Bell, PA – September 11, 2006 –

VGX Pharmaceuticals announced today the publication of preclinical animal efficacy studies for VGX-150, the company's lead product candidate for the treatment of melanoma. A manuscript entitled, "Complete Regression of Established Subcutaneous B16 Murine Melanoma Tumors after Delivery of an HIV-1 Vpr-Expressing Plasmid by in Vivo Electroporation," ([Download PDF](#)) was published in the online edition of *Molecular Therapy*, a leading journal of the American Society of Gene Therapy (ASGT).

The project was headed by Professors Kenneth E. Ugen and Richard Heller of the University of South Florida. The co-authors of the paper included VGX Co-founders, Dr. J. Joseph Kim and Professor David B. Weiner. The paper is now available online and should be available in the print edition in November.

This is the first report demonstrating the efficacy of VGX-150 delivered as a DNA plasmid with in vivo electroporation. The study findings indicated that treatment with VGX-150 resulted in complete tumor regression with long-term survival in a significant percentage of the mice in a highly aggressive and metastatic solid tumor model.

Soon to be a part of the prestigious Nature Publishing Group in January of 2007, *Molecular Therapy* presents important, peer-reviewed studies on key issues in gene transfer, gene and cell therapies, experimental models for correction of genetic and acquired disease and clinical trials. *Molecular Therapy* has become recognized as one of the most prestigious journals in the field, and is ranked in three ISI (Institute for Scientific Information) categories with a high impact factor.

"There continues to be a significant need for novel therapies and delivery methods directed against malignancies such as melanoma, and particularly metastatic melanoma. We believe VGX-150 can play an important role in the treatment of Melanoma, and we are pleased with the development progress of this important compound to date," said J. Joseph Kim, PhD., President and Chief Executive Officer of VGX Pharmaceuticals.

Manufacturing programs for VGX-150 under current Good Manufacturing Practices (cGMP) guidelines and the Investigational New Drug Application (IND) enabling animal toxicology testing have been initiated. An IND for VGX-150 is expected to be filed in early 2007 to support the initiation of Phase 1 clinical trials during the first quarter of 2007.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2007 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com